Olfr570 Inhibitors
Olfr570, a member of the olfactory receptor family, is intricately involved in the recognition and transduction of olfactory signals, contributing to the complex process of odorant perception. As a G-protein-coupled receptor (GPCR), Olfr570 shares a structural similarity with neurotransmitter and hormone receptors, utilizing a 7-transmembrane domain architecture for the recognition and transduction of odorant signals. The potential inhibition of Olfr570 involves targeting specific signaling pathways associated with its function. Tetrodotoxin and NBQX, acting as voltage-gated sodium channel and AMPA/kainate glutamate receptor antagonists, respectively, disrupt sodium and glutamatergic signaling pathways, leading to altered expression and function of Olfr570. Inhibitors such as Rotenone and Conotoxin GVIA affect Olfr570 indirectly by modulating mitochondrial electron transport and calcium channel activity, respectively.
Additionally, compounds like SB-431542, U0126, Wortmannin, Chlorotoxin, PD 153035, KN-62, Thapsigargin, and GW 5074 target various cellular processes, including TGF-β signaling, MAPK/ERK signaling, PI3 kinase signaling, chloride channel activity, EGFR signaling, CaMK signaling, calcium homeostasis, and c-Raf signaling, leading to altered expression and function of Olfr570. In summary, the potential inhibition of Olfr570 involves a diverse set of chemical inhibitors that target specific biochemical and cellular pathways associated with olfactory signal transduction. These inhibitors offer valuable insights into understanding and controlling the function of Olfr570 in the intricate process of odorant perception.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-Dione | 118876-58-7 | sc-478080 | 5 mg | $70.00 | 1 | |
AMPA/kainate glutamate receptor antagonist affecting Olfr570 indirectly. NBQX disrupts glutamatergic signaling pathways, leading to altered expression and function of Olfr570. | ||||||
Rotenone | 83-79-4 | sc-203242 sc-203242A | 1 g 5 g | $89.00 $259.00 | 41 | |
Complex I inhibitor influencing Olfr570 indirectly. Rotenone disrupts mitochondrial electron transport, modulating cellular metabolism and consequently leading to altered expression and function of Olfr570. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
TGF-β receptor inhibitor affecting Olfr570 through the TGF-β signaling pathway. SB-431542 disrupts TGF-β receptor activity, leading to altered expression and function of Olfr570 as a downstream consequence of pathway inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
MEK inhibitor affecting Olfr570 through the MAPK/ERK pathway. U0126 disrupts the MAPK/ERK signaling cascade, leading to altered expression and function of Olfr570 as a downstream consequence of pathway inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3 kinase inhibitor influencing Olfr570 through the PI3 kinase signaling pathway. Wortmannin disrupts PI3 kinase activity, modulating olfactory signaling pathways and consequently leading to altered expression and function of Olfr570. | ||||||
PD 153035 | 153436-54-5 | sc-205909 | 5 mg | $146.00 | 5 | |
EGFR inhibitor influencing Olfr570 through the EGFR signaling pathway. PD 153035 disrupts EGFR activity, modulating olfactory signaling pathways and consequently leading to altered expression and function of Olfr570. | ||||||
KN-62 | 127191-97-3 | sc-3560 | 1 mg | $136.00 | 20 | |
CaMK inhibitor affecting Olfr570 through the CaMK signaling pathway. KN-62 disrupts CaMK activity, modulating olfactory signaling pathways and consequently leading to altered expression and function of Olfr570. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
SERCA inhibitor affecting Olfr570 through calcium homeostasis. Thapsigargin disrupts SERCA activity, modulating olfactory signaling pathways and consequently leading to altered expression and function of Olfr570. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
c-Raf inhibitor affecting Olfr570 through the MAPK/ERK pathway. GW 5074 disrupts the MAPK/ERK signaling cascade, leading to altered expression and function of Olfr570 as a downstream consequence of pathway inhibition. | ||||||